Dr. Ghafoor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8600 Old Georgetown Road
Bethesda, MD 20814Phone+1 301-896-7610Fax+1 301-896-7626
Education & Training
Ascension St Vincent Hospital IndianapolisResidency, Internal Medicine, 2013 - 2016
Indiana University School of MedicineClass of 2013
Certifications & Licensure
MD State Medical License 2016 - 2026
DC State Medical License 2016 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib Start of enrollment: 2016 Apr 13
- LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2019 Sep 11
Publications & Presentations
PubMed
- 23 citationsPhase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene.Azam Ghafoor, Idrees Mian, Cathy Wagner, Yvonne Mallory, Maria Agra
JTO Clinical and Research Reports. 2021-10-01 - 23 citationsMesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.Raffit Hassan, Marcus Butler, Roisin E O'Cearbhaill, David Y Oh, Melissa Johnson
Nature Medicine. 2023-08-01 - 16 citationsMalignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.Zishuo I. Hu, Azam Ghafoor, Manjistha Sengupta, Raffit Hassan
Cancer. 2021-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
